Inogen (INGN) Cash from Operations Growth (3y) (2016 - 2026)

Inogen (INGN) Cash from Operations Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Abbott Laboratories 182.44 Bn 175.14 Bn 6.27 Bn 4.78%
2 Stryker 128.91 Bn 126.03 Bn 3.81 Bn 9.30%
3 Medtronic 108.67 Bn 99.45 Bn 6.41 Bn 1.51%
4 Boston Scientific 68.45 Bn 67.00 Bn 3.61 Bn 22.35%
5 Edwards Lifesciences 47.59 Bn 43.92 Bn 1.29 Bn -48.14%
6 Dexcom 28.59 Bn 27.48 Bn 750.30 Mn 50.11%
7 GE HealthCare Technologies 28.53 Bn 26.24 Bn 1.98 Bn -14.75%
8 Smith & Nephew 26.95 Bn 26.37 Bn - -
9 Koninklijke Philips 25.42 Bn 22.30 Bn 2.07 Bn 0.50%
10 Inogen 174.59 Mn 64.42 Mn 37.86 Mn -1.99%

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.99%
Dec 31, 2025 60.65%
Sep 30, 2025 30.62%
Jun 30, 2025 -7.69%
Mar 31, 2025 2.47%
Dec 31, 2024 -35.07%
Sep 30, 2024 63.06%
Jun 30, 2024 -27.10%
Mar 31, 2024 -54.12%
Dec 31, 2023 -29.95%
Sep 30, 2023 -31.32%
Jun 30, 2023 -33.22%
Mar 31, 2023 -139.10%
Dec 31, 2022 -53.95%
Sep 30, 2022 -38.37%
Jun 30, 2022 -33.05%
Mar 31, 2022 -114.88%
Dec 31, 2021 -19.24%
Sep 30, 2021 -30.22%
Jun 30, 2021 -6.35%